Results 21 to 30 of about 5,819 (161)

Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with heterozygosity [PDF]

Intestinal Research, 2022
Background/Aims Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be associated with thiopurine-induced adverse ...
Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Yoichi Kakuta, Hidezumi Kikuchi, Shogo Kawaguchi, Keisuke Hasui, Tetsuya Tatsuta, Daisuke Chinda, Tatsuya Mikami, Shinsaku Fukuda   +11 more
doaj   +1 more source

Use of thiopurines in inflammatory bowel disease: an update [PDF]

Intestinal Research, 2022
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD has come under the spotlight.
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Rakesh Kochhar, Rupa Banerjee, Saroj Kant Sinha, Siew Chien Ng, Stephen Hanauer, Suhang Verma, Usha Dutta, Vandana Midha, Varun Mehta, Vineet Ahuja, Ajit Sood   +25 more
doaj   +1 more source

Nudix Hydroxylase 15 Mutations Strongly Predict Thiopurine-Induced Leukopenia Across Different Asian Ethnicities: Implications for Screening in a Diverse Population

Frontiers in Medicine, 2022
Background and AimsThiopurines, which are immunosuppressive drugs for maintaining remission for inflammatory bowel disease, are known to cause myelotoxicity in patients with Nudix Hydroxylase 15 (NUDT15) genetic variants in some Asian countries with ...
Xin-Hui Khoo, Shin Yee Wong, Nik Razima Wan Ibrahim, Ruey Terng Ng, Kee Seang Chew, Way Seah Lee, Zhi Qin Wong, Raja Affend Raja Ali, Shahreedhan Shahrani, Alex Hwong-Ruey Leow, Ida Normiha Hilmi, Ida Normiha Hilmi   +11 more
doaj   +1 more source

Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising “MINT” sequencing strategy and therapeutic “DNA-TG” monitoring

Frontiers in Pharmacology, 2022
Thiopurines, including thioguanine (TG), 6-mercaptopurine (6-MP), and azathioprine (AZA), are extensively used in clinical practice in children with acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases.
Hong-Li Guo, Yue-Tao Zhao, Yue-Tao Zhao, Wei-Jun Wang, Wei-Jun Wang, Na Dong, Na Dong, Ya-Hui Hu, Yuan-Yuan Zhang, Feng Chen, Li Zhou, Tao Li   +11 more
doaj   +1 more source

Pharmacogenetics of thiopurines

Cancer Drug Resistance, 2019
Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia (ALL) always include thiopurines. Specific approaches vary in terms of drugs, dosages and combinations. Such therapeutic schemes, including risk-adapted intensity, have been extremely successful for children with ALL who have reached an outstanding 5-year ...
Raffaella Franca, ZUDEH, GIULIA, Sofia Pagarin, Marco Rabusin, Marianna Lucafò, Gabriele Stocco, Giuliana Decorti   +6 more
openaire   +3 more sources

Capillary Electrophoresis Hyphenated with Mass Spectrometry for Determination of Inflammatory Bowel Disease Drugs in Clinical Urine Samples

Molecules, 2017
Azathioprine is the main thiopurine drug used in the treatment of immune-based inflammations of gastrointestinal tract. For the purpose of therapy control and optimization, effective and reliable analytical methods for a rapid drug monitoring in ...
Katarína Maráková, Juraj Piešťanský, Zuzana Zelinková, Peter Mikuš   +3 more
doaj   +1 more source

Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.

PLoS ONE, 2016
ObjectiveLong-term treatment with thiopurines is associated with a decreased risk of Crohn's disease (CD) flare but an increased risk of various cancers depending on gender, age, and presence of extensive colitis.
Julien Kirchgesner, Laurent Beaugerie, Fabrice Carrat, Harry Sokol, Jacques Cosnes, Michaël Schwarzinger, BERENICE Study Group   +6 more
doaj   +1 more source

Taking Crohn’s Disease Personally

Rambam Maimonides Medical Journal, 2013
Crohn’s disease (CD) is a heterogeneous disorder that can involve any segment of the gastrointestinal tract. The pathogenesis of CD is unknown but is thought to involve an uncontrolled immune response triggered by an environmental factor in a genetically
Yehuda Chowers
doaj   +1 more source

Methotrexate in inflammatory bowel disease: A primer for gastroenterologists

The Saudi Journal of Gastroenterology, 2022
Methotrexate is an antineoplastic agent that is also used at lower doses for anti-inflammatory properties. Along with thiopurines (azathioprine and 6-mercaptopurine), it has historically been an important part of pharmacological treatment for patients ...
Turki AlAmeel, Eman Al Sulais, Tim Raine
doaj   +1 more source

Epstein-Barr Virus Infection and Thiopurine Therapy in a Pediatric Population with Inflammatory Bowel Disease

GE: Portuguese Journal of Gastroenterology, 2020
Epstein Barr virus (EBV) primoinfection may contribute to the development of post-mononucleosis lymphomas in EBV-seronegative adult males with inflammatory bowel disease (IBD) under thiopurine therapy, but data on children are sparse.
Maria Do Céu Espinheira, Isabel Pinto Pais, Ivete Afonso, Jorge Ferreira, Eunice Trindade, Jorge Amil-Dias   +5 more
doaj   +1 more source